Article Text

Download PDFPDF
Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma
  1. Kadri Altundag1,
  2. Didem S Dede1,
  3. Tugrul Purnak2
  1. 1Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey
  2. 2Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
  1. Correspondence to:
 Dr K Altundag
 Department of Medical Oncology, Hacettepe University Institute of Oncology, Sihhiye Ankara 06100, Turkey;altundag66{at}yahoo.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the paper by Banerjee et al1 regarding the clinical outcome and response to chemotherapy in basal-like carcinoma of the breast. After extensive discussion of chemotherapeutics used in the management of basal-like carcinoma, they concluded that new treatment options should be investigated for patients with this subtype of breast cancer. A recent study by Pinilla et al2 showed that caveolin-1 (CAV1) expression is associated with a basal-like phenotype in sporadic and hereditary breast cancers. They …

View Full Text

Footnotes

  • Competing interests: None declared.